secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001437749-26-001050
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin: MIRACLE trial unblinding on track for Q1 2026; global expansion to 9 countries
--------------------------------------------------------------------------------

- First unblinding of 45 subjects in pivotal Phase 2B/3 MIRACLE trial for 2L AML expected Q1 2026.
- Trial expanded to 9 countries with over 46 sites selected; next unblinding of 90 subjects expected Q3 2026.
- Atlantic Health to fund IIT with Annamycin in 3L pancreatic cancer; preclinical data show activity.
- WP1066 Phase 2 GBM trial at Northwestern continues; Emory to start pediatric brain tumor trial in 2H 2026.
- Non-cardiotoxicity review of Annamycin data to be presented Q1 2026; potential first non-cardiotoxic anthracycline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926001050/0001437749-26-001050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926001050/mbrx20260110_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-001050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer